老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
AgomAb Therapeutics
11.80
-0.3600
-2.96%
成交量：
3.85萬
成交額：
46.94萬
市值：
5.81億
市盈率：
-2.61
高：
12.58
開：
12.26
低：
11.63
收：
12.16
52周最高：
17.82
52周最低：
8.75
股本：
4,924.80萬
流通股本：
1,383.60萬
量比：
0.38
換手率：
0.28%
股息：
- -
股息率：
- -
每股收益(TTM):
-4.5143
每股收益(LYR):
-168.1598
淨資產收益率：
-39.22%
總資產收益率：
-20.58%
市淨率：
5.47
市盈率(LYR):
-0.07
資料載入中...
總覽
公司
新聞資訊
公告
Agomab Therapeutics：AGMB-447在IPF患者中展示出4.5毫克Bid劑量下的優越安全性與耐受性
美股速递
·
09/15
Agomab公布Agmb-447特發性肺纖維化1期積極結果及2期Inspiria研究設計
美股速递
·
09/15
Agomab宣佈Marino Garcia與Naimish Patel博士加入董事會
投资观察
·
09/12
Agomab公布Ontunisertib治療纖維狹窄型克羅恩病的新時代2B期研究設計方案
美股速递
·
06/24
Agomab獲美國專利授權 肺靶向吸入式ALK5小分子抑制劑AGMB-447進入特發性肺纖維化治療研發階段
美股速递
·
03/26
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/AGMB/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":11.8,"timestamp":1789584705521,"preClose":12.16,"halted":0,"volume":38452,"delay":0,"changeRate":-0.02960526315789469,"floatShares":13836000,"shares":49248000,"eps":-4.51426,"marketStatus":"交易中","change":-0.36,"latestTime":"09-16 14:52:32 EDT","open":12.26,"high":12.58,"low":11.634,"amount":469442.626272,"amplitude":0.077796,"askPrice":11.88,"askSize":200,"bidPrice":11.71,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-4.51426,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":12.16,"postHourTrading":{"tag":"盘后","latestPrice":12.16,"preClose":12.16,"latestTime":"19:30 EDT","volume":209,"amount":2541.44,"timestamp":1789515006387,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.381392},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":13836000,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":0.381392,"shares":49248000,"dividePrice":0,"high":12.58,"amplitude":0.077796,"preClose":12.16,"low":11.634,"week52Low":8.75,"pbRate":"5.47","week52High":17.82,"institutionHeld":0,"latestPrice":11.8,"committee":-0.818182,"eps":-4.51426,"divideRate":0,"volume":38452,"delay":0,"ttmEps":-4.51426,"open":12.26,"prevYearClose":16,"prevWeekClose":13.06,"prevMonthClose":13.17,"prevQuarterClose":12.98,"fiveDayClose":14.96,"twentyDayClose":13.73,"sixtyDayClose":11.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1787716800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-09-15","current":-2.613939,"percent":0.806667,"low":-14.725744,"twenty":-11.744798,"median":-8.931525,"eighty":-7.884799,"high":-6.52172,"avg":-9.591466,"sd":2.186893,"marketCap":604765133},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631},{"date":"2026-06-05","current":-8.053102,"twenty":-13.287949,"median":-9.784729,"eighty":-7.758816,"marketCap":585558422},{"date":"2026-06-12","current":-6.750851,"twenty":-13.127527,"median":-9.578953,"eighty":-7.536224,"marketCap":486569993},{"date":"2026-06-18","current":-6.929006,"twenty":-13.073014,"median":-9.501773,"eighty":-7.448225,"marketCap":497404547},{"date":"2026-06-26","current":-9.2886,"twenty":-13.035188,"median":-9.467948,"eighty":-7.458553,"marketCap":661400304},{"date":"2026-07-02","current":-8.166663,"twenty":-12.965993,"median":-9.467948,"eighty":-7.479819,"marketCap":584573463},{"date":"2026-07-10","current":-8.975013,"twenty":-12.944797,"median":-9.309036,"eighty":-7.532768,"marketCap":641701114},{"date":"2026-07-17","current":-8.479177,"twenty":-12.71107,"median":-9.193391,"eighty":-7.541408,"marketCap":606735052},{"date":"2026-07-24","current":-8.981683,"twenty":-12.707304,"median":-9.020605,"eighty":-7.554336,"marketCap":638746235},{"date":"2026-07-31","current":-8.723327,"twenty":-12.661785,"median":-8.978348,"eighty":-7.610114,"marketCap":628157921},{"date":"2026-08-07","current":-9.22434,"twenty":-12.557349,"median":-9.00807,"eighty":-7.636377,"marketCap":664847662},{"date":"2026-08-14","current":-8.931525,"twenty":-12.519309,"median":-9.035172,"eighty":-7.716456,"marketCap":686763011},{"date":"2026-08-21","current":-8.496488,"twenty":-12.423423,"median":-8.981683,"eighty":-7.781927,"marketCap":661400304},{"date":"2026-08-28","current":-8.778373,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"marketCap":681591974},{"date":"2026-09-04","current":-9.428222,"twenty":-12.300242,"median":-8.931525,"eighty":-7.867232,"marketCap":730347469},{"date":"2026-09-11","current":-8.858281,"twenty":-11.959423,"median":-8.973278,"eighty":-7.956453,"marketCap":686516771},{"date":"2026-09-15","current":-7.859678,"twenty":-11.744798,"median":-8.931525,"eighty":-7.884799,"marketCap":604765133}],"updateTime":1789584752875},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1108737836","title":"Agomab Therapeutics：AGMB-447在IPF患者中展示出4.5毫克Bid劑量下的優越安全性與耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1108737836","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108737836?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 04:13","pubTimestamp":1789416788,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics公司今日宣布，其候选药物AGMB-447在特发性肺纤维化（IPF）患者中展现出令人鼓舞的安全性和耐受性数据。该项研究聚焦于4.5毫克每日两次（Bid）的给药方案，初步结果令人振奋。\n数据表明，该剂量水平下的药物耐受性表现良好，患者未出现预期之外的不良事件。这一发现为AGMB-447的后续临床开发奠定了坚实基础。\n作为一家专注于纤维化疾病治疗领域的生物制药企业，Agomab Therapeutics正积极推进该候选药物的临床研究进程。此次公布的结果进一步验证了公司在纤维化治疗管线上的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108518383","title":"Agomab公布Agmb-447特發性肺纖維化1期積極結果及2期Inspiria研究設計","url":"https://stock-news.laohu8.com/highlight/detail?id=1108518383","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108518383?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 04:06","pubTimestamp":1789416373,"startTime":"0","endTime":"0","summary":"Agomab近日对外宣布，其针对特发性肺纤维化患者所研发的在研药物Agmb-447，在1期临床试验中取得了令人振奋的积极数据。与此同时，该公司还正式揭晓了即将启动的2期临床研究——Inspiria研究的设计方案。关于2期Inspiria研究的规划，Agomab表示将基于1期所确立的给药方案与剂量范围，进一步深入评估Agmb-447在更大规模患者群体中的疗效与安全性。随着2期研究的即将铺开，业内目光已聚焦于Agomab能否延续其研发势能，以及Inspiria研究最终能收获怎样的临床答卷。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188543400","title":"Agomab宣佈Marino Garcia與Naimish Patel博士加入董事會","url":"https://stock-news.laohu8.com/highlight/detail?id=1188543400","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188543400?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:06","pubTimestamp":1789157208,"startTime":"0","endTime":"0","summary":"比利时安特卫普，2026年9月11日——专注于纤维炎症性疾病的临床阶段生物制药公司Agomab Therapeutics NV今日宣布，在2026年9月11日召开的特别及非常股东大会中，股东已批准提交审议的全部决议。获批决议包括任命Marino Garcia和Naimish Patel博士为公司非执行董事会成员，以及对首次公开募股前未行使认股权证进行合并及拆股调整的提案。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPO","AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186837702","title":"Agomab公布Ontunisertib治療纖維狹窄型克羅恩病的新時代2B期研究設計方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1186837702","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186837702?lang=zh_tw&edition=fundamental","pubTime":"2026-06-24 04:06","pubTimestamp":1782245174,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics公司宣布，已为其候选药物Ontunisertib针对纤维狭窄型克罗恩病的治疗，完成了名为“Nov-Era”的2B期临床研究方案设计。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184179798","title":"Agomab獲美國專利授權 肺靶向吸入式ALK5小分子抑制劑AGMB-447進入特發性肺纖維化治療研發階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1184179798","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184179798?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522815,"startTime":"0","endTime":"0","summary":"生物制药企业AgomAb Therapeutics宣布，其研发的肺靶向吸入式ALK5小分子抑制剂AGMB-447已获得美国专利授权。该药物目前正针对特发性肺纤维化适应症开展临床前研究，通过精准抑制肺泡区域的TGF-β信号通路，有望为患者提供创新治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}